Theratechnologies Inc. (?Theratechnologies? or the ?Company?) has received correspondence from the U.S. Food and Drug Administration (FDA) regarding the Company?s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin. The FDA has notified the Company that it is continuing its review of the application beyond the Prescription Drug User Fee Act (PDUFA) goal date of January 22, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.97 CAD | +1.03% |
|
+5.35% | -7.94% |
Jul. 10 | Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 | CI |
Jul. 10 | Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.94% | 66.53M | |
+6.96% | 101B | |
+8.29% | 42.63B | |
-11.09% | 33.5B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B |
- Stock Market
- Equities
- TH Stock
- News Theratechnologies Inc.
- Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application